Vontobel Holding Ltd. Decreases Stock Holdings in Allakos Inc. (NASDAQ:ALLK)

Vontobel Holding Ltd. trimmed its position in shares of Allakos Inc. (NASDAQ:ALLK) by 2.3% during the 4th quarter, Holdings Channel reports. The fund owned 752,381 shares of the company’s stock after selling 17,751 shares during the period. Vontobel Holding Ltd.’s holdings in Allakos were worth $2,054,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Allakos by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,265,631 shares of the company’s stock worth $7,413,000 after acquiring an additional 16,973 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Allakos by 23.5% during the 3rd quarter. Deutsche Bank AG now owns 34,879 shares of the company’s stock worth $79,000 after acquiring an additional 6,643 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Allakos by 81.1% during the 3rd quarter. Redmile Group LLC now owns 4,135,061 shares of the company’s stock worth $9,387,000 after acquiring an additional 1,851,467 shares in the last quarter. Sectoral Asset Management Inc. raised its holdings in Allakos by 77.3% during the 3rd quarter. Sectoral Asset Management Inc. now owns 770,132 shares of the company’s stock valued at $1,748,000 after buying an additional 335,822 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Allakos by 285.4% during the 3rd quarter. AQR Capital Management LLC now owns 71,837 shares of the company’s stock valued at $163,000 after buying an additional 53,199 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

Allakos Price Performance

ALLK stock opened at $1.06 on Friday. The business’s fifty day simple moving average is $1.29 and its two-hundred day simple moving average is $1.84. Allakos Inc. has a twelve month low of $1.00 and a twelve month high of $5.64. The firm has a market cap of $93.14 million, a price-to-earnings ratio of -0.50 and a beta of 0.82.

Allakos (NASDAQ:ALLK) last released its earnings results on Thursday, March 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.18). Research analysts expect that Allakos Inc. will post -1.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ALLK shares. Cantor Fitzgerald lowered Allakos from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 16th. JMP Securities decreased their price target on Allakos from $10.00 to $3.00 and set a “market outperform” rating on the stock in a report on Wednesday, January 17th. Barclays decreased their price target on Allakos from $1.50 to $1.00 and set an “underweight” rating on the stock in a report on Wednesday, January 17th. Finally, Jefferies Financial Group lowered Allakos from a “buy” rating to a “hold” rating and decreased their price target for the company from $6.00 to $1.50 in a report on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $1.83.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.